Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05945368 | A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 14, 2023 |
| clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)(HYPERION) | unknown | Phase 2 | 128 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05576909 | Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | unknown | Phase 2 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05879497 | 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion | unknown | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05879510 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | unknown | Phase 2 | 63 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 35 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02365441 | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)(ALT GIST) | unknown | Phase 2 | 78 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Jul 7, 2023 | clinicaltrials |
| NCT05631912 | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL | unknown | Phase 1 / Phase 2 | 38 | Chinese PLA General HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05925413 | Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 41 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01374841 | Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors | unknown | Phase 2 | 20 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03001570 | Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District(FAMOSO) | unknown | Phase 2 | 10 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine(TaRRGET) | unknown | Phase 2 | 40 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | unknown | Phase 2 | 60 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03809780 | Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone(LENDER) | unknown | Phase 2 | 70 | Kosin University Gospel HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05912205 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02396043 | Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03641456 | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05900765 | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05908916 | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 51 | Yonsei UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05902377 | 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma | unknown | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT04480099 | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 2 | 96 | Ruijin HospitalOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma(LEGEND-2) | unknown | Phase 1 / Phase 2 | 100 | Nanjing Legend Biotech Co.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 20 | Genexine, Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05900219 | Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | unknown | Phase 2 | 75 | Shanghai Kechow Pharma, Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05895864 | Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05896059 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05896787 | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05893472 | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05106023 | To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma | unknown | Phase 2 | 31 | Yong ChenOTHER | 1 | Jun 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2023source: clinicaltrials